Communities That HEAL干预对获得丁丙诺啡豁免处方资格从业者及丁丙诺啡处方的影响:HCS随机临床试验的预设二次分析
该研究为HEALing Communities Study的预设二次分析,采用多站点、2组、平行、社区层面整群随机、开放、等待列表对照设计,于2020年1月1日至2023年12月31日在肯塔基州、马萨诸塞州、纽约州和俄亥俄州的67个社区(48个县和19个市镇)进行,覆盖约820万成人。干预为研究站点提供或支持豁免培训及其他教育培训以帮助建设从业者能力。主要比较2021年7月1日至2022年6月30日期间每10万18岁及以上成年居民中持有DATA 2000豁免的从业者率(总体及按30、100、275例患者限制分层)以及豁免从业者中丁丙诺啡处方率。结果显示,干预对调整后豁免从业者率(ARR 1.04;95% CI 0.94-1.14)或调整后活跃开具丁丙诺啡处方的豁免从业者率(ARR 0.97;95% CI 0.86-1.10)均无效应证据。作者认为,支持从业者开具丁丙诺啡仍是治疗阿片类药物使用障碍连续护理中关键但具有挑战性的一步。
要点
- 在67个社区中,Communities That HEAL干预未增加调整后DATA 2000豁免从业者率(ARR 1.04;95% CI 0.94-1.14)。
- 干预也未增加调整后活跃开具丁丙诺啡处方的豁免从业者率(ARR 0.97;95% CI 0.86-1.10)。
- 研究纳入8 166 963名18岁及以上居民,比较期为2021年7月1日至2022年6月30日。
- 作者认为,支持从业者开具丁丙诺啡仍是治疗阿片类药物使用障碍连续护理中关键但具挑战性的一步。
适用人群与场景
- 肯塔基州、马萨诸塞州、纽约州和俄亥俄州的67个社区(48个县和19个市镇),约820万成人。
- 分析纳入8 166 963名18岁及以上居民,比较2021年7月1日至2022年6月30日期间的数据。
处置流程与药物剂量
- 干预措施:由各州HEALing Communities Study研究站点提供或支持豁免培训及其他教育培训,以帮助建设从业者能力。
研究设计与关键结果
- 研究设计:HEALing Communities Study的预设二次分析,多站点、2组、平行、社区层面整群随机、开放、等待列表对照临床试验;67个社区按州分层协变量约束随机化,34个社区随机至干预组、33个至等待列表对照组;采用意向治疗和符合方案分析。
- 主要终点:调整后DATA 2000豁免从业者率,干预组与对照组比较ARR 1.04(95% CI 0.94-1.14)。
- 主要终点:调整后活跃开具丁丙诺啡处方的豁免从业者率,干预组与对照组比较ARR 0.97(95% CI 0.86-1.10)。
- 共8 166 963名18岁及以上居民居住在67个社区。
- 试验注册号:ClinicalTrials.gov NCT04111939。
证据类型、等级与局限
- 证据类型:随机临床试验(多站点、2组、平行、社区层面整群随机、开放、等待列表对照)的预设二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,支持从业者开具丁丙诺啡仍是治疗阿片类药物使用障碍连续护理中关键但具挑战性的一步;本研究未显示Communities That HEAL干预增加豁免从业者率或丁丙诺啡处方率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Buprenorphine significantly reduces opioid-related overdose mortality. From 2002 to 2022, the Drug Addiction Treatment Act of 2000 (DATA 2000) required qualified practitioners to receive a waiver from the Drug Enforcement Agency to prescribe buprenorphine for treatment of opioid use disorder. During this period, waiver uptake among practitioners was modest; subsequent changes need to be examined.
OBJECTIVE: To determine whether the Communities That HEAL (CTH) intervention increased the rate of practitioners with DATA 2000 waivers and buprenorphine prescribing.
DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary analysis of the HEALing Communities Study, a multisite, 2-arm, parallel, community-level, cluster randomized, open, wait-list-controlled comparison clinical trial was designed to assess the effectiveness of the CTH intervention and was conducted between January 1, 2020, to December 31, 2023, in 67 communities in Kentucky, Massachusetts, New York, and Ohio, accounting for approximately 8.2 million adults. The participants in this trial were communities consisting of counties (n = 48) and municipalities (n = 19). Trial arm randomization was conducted using a covariate constrained randomization procedure stratified by state. Each state was balanced by community characteristics including urban/rural classification, fatal opioid overdose rate, and community population. Thirty-four communities were randomized to the intervention and 33 to wait-list control arms. Data analysis was conducted between March 20 and September 29, 2023, with a focus on the comparison period from July 1, 2021, to June 30, 2022.
INTERVENTION: Waiver trainings and other educational trainings were offered or supported by the HEALing Communities Study research sites in each state to help build practitioner capacity.
MAIN OUTCOMES AND MEASURES: The rate of practitioners with a DATA 2000 waiver (overall, and stratified by 30-, 100-, and 275-patient limits) per 100 000 adult residents aged 18 years or older during July 1, 2021, to June 30, 2022, were compared between the intervention and wait-list control communities. The rate of buprenorphine prescribing among those waivered practitioners was also compared between the intervention and wait-list control communities. Intention-to-treat and per-protocol analyses were performed.
RESULTS: A total of 8 166 963 individuals aged 18 years or older were residents of the 67 communities studied. There was no evidence of an effect of the CTH intervention on the adjusted rate of practitioners with a DATA 2000 waiver (adjusted relative rate [ARR], 1.04; 95% CI, 0.94-1.14) or the adjusted rate of practitioners with a DATA 2000 waiver who actively prescribed buprenorphine (ARR, 0.97; 95% CI, 0.86-1.10).
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the CTH intervention was not associated with increases in the rate of practitioners with a DATA 2000 waiver or buprenorphine prescribing among those waivered practitioners. Supporting practitioners to prescribe buprenorphine remains a critical yet challenging step in the continuum of care to treat opioid use disorder.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04111939.
参考来源
- Stopka TJ, Babineau DC, Gibson EB, et al. Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38386322. doi:10.1001/jamanetworkopen.2024.0132
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。